Now showing items 1-2 of 2

    • Clinical Trials: Rethinking How We Ensure Quality 

      Landray, MJ; Grandinetti, C; Kramer, JM; Morrison, BW; Ball, L; Sherman, RE (Drug Information Journal, 2012-11-01)
    • Spending on postapproval drug safety. 

      Grabowski, Henry G; Kramer, JM; Ridley, David Blaine; Schulman, Kevin Alan; Tilson, HH (Health Aff (Millwood), 2006-03)
      Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...